Royal Bank Of Canada Issues Positive Forecast for Nuvation Bio (NYSE:NUVB) Stock Price

Nuvation Bio (NYSE:NUVB) had its target price upped by Royal Bank Of Canada from $12.00 to $13.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

NUVB has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, January 22nd. B. Riley Financial started coverage on shares of Nuvation Bio in a research report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 price target for the company. HC Wainwright dropped their price objective on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a research note on Tuesday, February 10th. Finally, UBS Group initiated coverage on Nuvation Bio in a report on Wednesday, January 7th. They set a “neutral” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.44.

Nuvation Bio Stock Down 25.2%

Shares of NYSE:NUVB opened at $4.37 on Tuesday. The business’s 50 day moving average is $6.55 and its 200 day moving average is $5.54. The stock has a market cap of $1.50 billion, a P/E ratio of -7.28 and a beta of 1.50. Nuvation Bio has a 52-week low of $1.54 and a 52-week high of $9.75. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative return on equity of 54.90% and a negative net margin of 325.31%.The business had revenue of $41.87 million during the quarter, compared to analysts’ expectations of $36.82 million. Sell-side analysts predict that Nuvation Bio will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Nuvation Bio

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Nuvation Bio by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock worth $139,378,000 after purchasing an additional 101,011 shares in the last quarter. Geode Capital Management LLC raised its stake in Nuvation Bio by 16.8% in the second quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock valued at $11,691,000 after buying an additional 864,194 shares during the last quarter. Millennium Management LLC raised its stake in Nuvation Bio by 52.4% in the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after buying an additional 1,298,131 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Nuvation Bio by 19.9% in the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock worth $12,276,000 after acquiring an additional 551,508 shares in the last quarter. Finally, Aisling Capital Management LP grew its stake in shares of Nuvation Bio by 16.5% during the third quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock worth $10,954,000 after acquiring an additional 419,650 shares during the last quarter. 61.67% of the stock is owned by institutional investors and hedge funds.

More Nuvation Bio News

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Strong commercial traction for IBTROZI: company reported 216 new patient starts in Q4 and 432 total starts since launch, and highlighted rapid adoption across treatment lines — supports revenue growth expectations and commercial momentum. PR Newswire: Q4 results & business update
• Positive Sentiment: Strategic collaboration: exclusive licensing/collaboration agreement with Eisai for taletrectinib in Europe and additional territories expands commercialization reach and derisks regional launch execution. PR Newswire: Eisai collaboration
• Positive Sentiment: Revenue beat and strong liquidity: Q4 revenue of $41.87M topped consensus (~$36.8M) and company reported $529.2M in cash, cash equivalents and marketable securities — gives runway for commercialization and R&D. Zacks: Q4 revenue beat
• Positive Sentiment: Clinical progress beyond IBTROZI: published positive Phase 2 safusidenib results showing durable responses in IDH1-mutant glioma and ongoing SIGMA protocol amendment — supports pipeline optionality. FinanzNachrichten: Q4 results & safusidenib update
• Neutral Sentiment: Earnings cadence: GAAP EPS loss of ($0.11) matched consensus (improved versus prior year loss) — meets expectations but is not an upside catalyst on its own. MarketBeat: Q4 EPS & call
• Neutral Sentiment: Management commentary & strategy: Q4 call and presentations outline first-line IBTROZI growth strategy and longer median DOR messaging — informative but will take time to convert into durable financial gains. Seeking Alpha: IBTROZI strategy
• Negative Sentiment: Analyst downgrade and target cut from UBS: UBS lowered its price target from $10 to $7 and moved to “neutral” — a direct negative signal that likely pressured the stock. Benzinga: UBS target cut
• Negative Sentiment: Profitability concerns remain: company still posts large negative net margins and negative ROE despite revenue growth — a reminder that commercial ramp must outpace costs to justify higher valuations. MarketBeat: financial metrics

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.